EN DE
Watch Biotalys NV for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Biotalys NV (BTLS) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Biotalys NV stock €0.99, price €1.97, that is 49.6% below the price, quality 37 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Basic Materials BE · ISIN BE0974386188

BN Biotalys NV logo Thin data Nov 10, 2026

Biotalys NV

BTLS · BR
Very expensive, weak quality

Our calculation puts a fair price 50% below what the stock costs today.

Low debt
Revenue last quarter 40% below a year ago.
Fair value €0.9900 · Strongly overvalued
Quality 37/100
Negative free cash flow
Trails peers (0/7)
Narrow moat 16/100
Thin data
⟳ CyclicalEstimate
Watch Biotalys NV for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

€7.46 €1.61 Fair Value €0.9900 Sep 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range €1.61 – €7.46 · fair‑value band €0.7400 – €1.23 · the €1.97 price screens above the €0.9900 fair value. As of Nov 10, 2026.

Follow Biotalys in your weekly email

Every Wednesday you see whether Biotalys is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Biotalys NV, an agricultural technology company, discovers and develops protein-based biocontrol solutions in Belgium and internationally. The company offers biofungicides and bioinsecticides.

Show moreShow less

It also provides the AGROBODY Foundry technology platform, which generates protein-based crop protection products.

In addition, the company develops EVOCA 1st generation, EVOCA Next generation, and BIOFUN-6 targeting botrytis, powdery mildew, and other fungi in fruits and vegetables; BIOFUN-7 targeting leafspot disease in cowpeas and other legumes; BIOFUN-4 targeting oomycetes in fruits and vegetables; BIOFUN-8 targeting altenaria in fruits, vegetables, and specialty crops; and BioIns-2 targeting key insect pests.

The company was formerly known as Agrosavfe NV and changed its name to Biotalys NV in December 2019. Biotalys NV was incorporated in 2013 and is headquartered in Ghent, Belgium.

Stock analysis

Biotalys NV (BTLS) currently trades at €1.97, while our estimate is €0.9900, 50% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: €0.7400 (bear) to €1.23 (bull), the price of €1.97 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 37/100 (below-average quality), in the Basic Materials sector.

Biotalys NV reported revenue of €0 in FY2025 versus €0 in FY2021. Reported net income was −€15.8M in FY2025.

Key figures

Market cap €77.2M Micro · EPS (TTM) €−0.4300 · Return on equity −96.4% · Return on assets (EBIT) −49.1% (5-year average) · Operating margin −438% · Revenue (TTM) €266K · Revenue growth (YoY) −40.4% · Free cash flow −€13.9M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 16 out of 100 (medium confidence).

What moves the price

The share trades about 60% below its 52-week high and 22% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Basic Materials peers we cover trades at 4% fair-value upside, at −50%, BTLS screens richer than that median.

Fair Value

Bear €0.7400 Fair Value €0.9900 Bull €1.23
Price €1.97 · Downside -49.6%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 37/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 25
Are margins and returns getting better?
Cashflow 25
Do the profits arrive as real cash?
Financial strength 72
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 15
How calm the share price moves, does not count
Price momentum 8
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 6
Distance to the 52-week high, does not count
New shares 17
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

BTLS screens overvalued: fair value 50% below the price. Compare with Nutrien Ltd →

Compare Biotalys NV with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Agricultural Inputs · 175 stocks

Beats the industry median on 0/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 37 · Bottom 25%
Fair Value upside −49.6% · Bottom 25%
Profitability
Return on assets −79.9% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −40.4% · Bottom 25%
Balance sheet
Debt / equity 0.50× · Highest 25%

Valuation Multiplesvs Agricultural Inputs median · lower = cheaper

P/B 6.38× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 17
FUTURE (revenue growth)0 · sector 14
PAST (return on equity)0 · sector 25
HEALTH (low debt)75 · sector 97
DIVIDEND (yield)0 · sector 40

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Agricultural Inputs stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Qinghai Salt Lake Industry Co 000792 ¥22.35 ¥26.81 +20% vs BTLS
Asia-potash International Investment (Guangzhou)Co.,Ltd., 000893 ¥31.99 ¥38.01 +19% vs BTLS
Nutrien Ltd NTR $72.17 $83.09 +15% vs BTLS
The Mosaic Company MOS $22.99 $25.77 +12% vs BTLS
Yara International ASA YAR kr 403.50 kr 419.83 +4% vs BTLS
ICL Group ICL $4.67 $4.84 +4% vs BTLS
CF Industries Holdings CF $122.36 $114.88 −6% vs BTLS
UPL Limited UPL ₹541.50 ₹478.29 −12% vs BTLS
Yunnan Yuntianhua Co 600096 ¥26.28 ¥17.67 −33% vs BTLS
Coromandel International Limited COROMANDEL ₹1,879 ₹1,129 −40% vs BTLS

Explore undervalued stocks

More undervalued Basic Materials stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Biotalys NV: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Biotalys NV Fair Value". https://www.fairvalue-calculator.com/stock/BTLS

Frequently asked questions

Is Biotalys NV (BTLS) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is €0.9900 versus a price of €1.97, about 50% lower (overvalued).
What is the fair value of BTLS?
Our estimate for Biotalys NV is €0.9900 (as of Nov 10, 2026), built from audited fundamentals. The current price: €1.97.
What is the quality score of BTLS?
Biotalys NV has a Quality Score of 37/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Biotalys NV (BTLS)?
Our calculated price target is the estimate of €0.9900 (as of Nov 10, 2026). Cautious scenario €0.7400, optimistic scenario €1.23. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Biotalys NV stock forecast for 2026?
Our estimate puts fair value at €0.9900, about 50% lower versus a price of €1.97 (overvalued). Cautious scenario €0.7400, optimistic scenario €1.23. The calculation is refreshed regularly with new filings.
What is the revenue of Biotalys NV (BTLS)?
Biotalys NV reported trailing-twelve-month revenue of about €266K (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Biotalys NV (BTLS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Biotalys NV it is €0.9900 per share (as of Nov 10, 2026), against a price of €1.97.
Is Biotalys NV stock overvalued or undervalued in 2026?
As of Nov 10, 2026, BTLS trades above its calculated fair value: price €1.97, fair value €0.9900, a gap of about −50% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BTLS?
No. The price is what the market pays today (€1.97); the fair value is what the company's own numbers justify (€0.9900). For Biotalys NV the two are €0.9760 per share apart. That gap is exactly why we show both numbers side by side.
How much is Biotalys NV worth?
The market values Biotalys NV at about €77.2M (market capitalisation, as of Nov 10, 2026). Per share that is €1.97; our models calculate a fair value of €0.9900 per share.
What do the bullish and bearish scenarios say about BTLS?
Our models span a range for Biotalys NV: cautious scenario €0.7400, base €0.9900, optimistic €1.23 per share (as of Nov 10, 2026, price €1.97). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Biotalys NV (BTLS)?
Balance-sheet figures for Biotalys NV (as of Nov 10, 2026): return on equity −96.4%, debt of 0.50 per unit of equity. They feed the Quality Score of 37/100, which measures business quality independently of the share price.
How far is BTLS from its 52-week high?
Biotalys NV trades at €1.97, about 60% below its 52-week high of €4.88 and 22% above the low of €1.61 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of €0.9900 is for.
Which stocks are comparable to Biotalys NV?
From the same area (Basic Materials) we also value Nutrien Ltd, Qinghai Salt Lake Industry Co, CF Industries Holdings, Yara International ASA, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Biotalys NV stock attractive at the current price?
The data as of Nov 10, 2026: price €1.97, calculated fair value €0.9900 (−50%), Quality Score 37/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Biotalys NV itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Biotalys NV (BTLS)?
The closing price on Nov 10, 2026 was €1.97. Our estimate is €0.9900, about 50% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Biotalys NV right now?
The price sits above even our optimistic bull case (€1.23). The favourable scenario is already priced in. Weak quality (37/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Biotalys NV

How large is the market capitalisation of Biotalys NV (BTLS)?
The market capitalisation of Biotalys NV is €77.2M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Biotalys NV (BTLS)?
Earnings per share at Biotalys NV are €−0.4300. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Biotalys NV (BTLS)?
The return on equity (ROE) of Biotalys NV is −96.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Biotalys NV (BTLS)?
On an EBIT basis the return on assets of Biotalys NV is −49.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Biotalys NV (BTLS)?
The operating margin of Biotalys NV is −438% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Biotalys NV (BTLS)?
Revenue at Biotalys NV is growing −40.4% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Biotalys NV (BTLS) generate?
The free cash flow of Biotalys NV is −€13.9M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Biotalys NV (BTLS) hold?
Biotalys NV holds more cash than debt, €8.0M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Biotalys NV in the live analysis

One click puts Biotalys NV on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.